Evgen Pharma (EVG) Rating Reiterated by FinnCap

FinnCap restated their corporate rating on shares of Evgen Pharma (LON:EVG) in a report issued on Thursday morning, ThisIsMoney.Co.Uk reports. They currently have a GBX 35 ($0.46) price objective on the stock, down from their previous price objective of GBX 45 ($0.59).

Shares of EVG stock opened at GBX 19.75 ($0.26) on Thursday. The firm has a market capitalization of $19.55 million and a price-to-earnings ratio of -6.58. Evgen Pharma has a 52 week low of GBX 12.70 ($0.17) and a 52 week high of GBX 33 ($0.43).

About Evgen Pharma

Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.

See Also: Systematic Risk and Investors

Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.